Results 31 to 40 of about 663,256 (217)

Progression-free survival after front line, second line and third line in patients with follicular lymphoma treated in clinical practice

Acta Oncologica
Background: The modern-day therapeutic landscape for follicular lymphoma (FL) includes a number of highly effective therapies. Patients and methods: We set out to determine progression-free survival (PFS) after front line, second line, and third line of
Aino Rajamaki, Marc Sorigue, Roosa E.I. Prusila, Milla E.L. Kuusisto, Hanne Kuitunen, Esa Jantunen, Santiago Mercadal, Taina Turpeenniemi-Hujanen, Juan-Manuel Sancho, Kaisa Sunela, Outi Kuittinen   +10 more
doaj   +1 more source

The role of temozolomide as adjuvant therapy in glioblastoma management: a systematic review and meta-analysis.

BMC Cancer
Introduction The persistent challenge of temozolomide (TMZ) resistance and the eventual recurrence of tumors underscore the need for ongoing research and the development of novel therapeutic strategies.
Made Agus Mahendra Inggas, Utsav Patel, Jeremiah Hilkiah Wijaya, Nina Otinashvili, Vyshnav Rajagopal Menon, Abhay Krishnan Iyer, Tawfiq Turjman, Surbhi Dadwal, Mari Gadaevi, Azada Ismayilova, Shiva Jashwanth Gaddam, Prakriti Arya, Nihar Upadhyay, Saurabh Kataria   +13 more
doaj   +1 more source

Progression-free survival versus post-progression survival and overall survival in WHO grade 2 gliomas

Acta Oncologica
Background and purpose: Progression-free survival (PFS) remains to be validated as an outcome measure for diffuse WHO grade 2 gliomas, and knowledge about the relationships between PFS, post-progression survival (PPS), and overall survival (OS) in this ...
Lisa Millgård Sagberg, Øyvind Salvesen, Asgeir Store Jakola, Erik Thurin, Eddie de Dios, Noah L.A. Nawabi, John L. Kilgallon, Joshua D. Bernstock, Vasileios K. Kavouridis, Timothy R. Smith, Ole Solheim   +10 more
doaj   +1 more source

Durvalumab supplementation for non-small-cell lung cancer: a meta-analysis study

Journal of Cardiothoracic Surgery
Background Durvalumab supplementation may have some potential in improving the efficacy in patients with non-small-cell lung cancer (NSCLC), and this meta-analysis aims to explore the impact of durvalumab supplementation on efficacy for NSCLC.
Chengchen Wang, Hongyi Fu, Feng Wang
doaj   +1 more source

Interpreting overall survival results when progression-free survival benefits exist in today's oncology landscape: a metastatic renal cell carcinoma case study

Cancer Management and Research, 2014
Yiyun Tang,1 Paul Bycott,1 Örjan Åkerborg,2 Linus Jönsson,2 Sylvie Negrier,3 Connie Chen4 1Pfizer Global Research and Development, La Jolla, CA, USA; 2OptumInsight, Stockholm, Sweden; 3Medical Oncology Department, University of Lyon, Lyon,
Tang Y, Bycott P, Åkerborg Ö, Jönsson L, Negrier S, Chen C   +5 more
doaj  

Long Non-Coding RNAs ASB16-AS1 and AFAP1-AS1: Diagnostic, Prognostic Impact and Survival Analysis in Colorectal Cancer

The Application of Clinical Genetics, 2022
Naglaa S Elabd,1 Shimaa E Soliman,2 Moamena S Elhamouly,1 Suzy F Gohar,3 Ayman Elgamal,4 Mahmoud Magdy Alabassy,5 Haitham A Soliman,5 Abdelnaser A Gadallah,6 Osama D Elbahr,7 Ghada Soliman,3 Amany A Saleh2 1Tropical Medicine Department, Faculty of ...
Elabd NS, Soliman SE, Elhamouly MS, Gohar SF, Elgamal A, Alabassy MM, Soliman HA, Gadallah AA, Elbahr OD, Soliman G, Saleh AA   +10 more
doaj  

Long Term Clinical Outcomes of Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Single Center Study [PDF]

The Korean Journal of Helicobacter and Upper Gastrointestinal Research
Objectives Few studies have reported long-term follow-up after treatment of gastric mucosaassociated lymphoid tissue (MALT) lymphoma. In this single-center study, we investigated longterm treatment outcomes in patients diagnosed with gastric MALT ...
Seong Hyun Koh, Seung Hyun Yeo, Moo In Park, Kyoungwon Jung, Sung Eun Kim, Won Moon, Seun Ja Park   +6 more
doaj   +1 more source

Improved clinical outcomes in advanced hepatocellular carcinoma treated with transarterial chemoembolization plus atezolizumab and bevacizumab: a bicentric retrospective study

BMC Cancer, 2023
Purpose The aim of the present study was to assess the efficacy and safety of transarterial chemoembolization (TACE) combined with atezolizumab and bevacizumab (hereafter, TACE-Atez/Bev) in the treatment of advanced hepatocellular carcinoma (HCC ...
Fei Cao, Changsheng Shi, Guofu Zhang, Jun Luo, Jiaping Zheng, Weiyuan Hao   +5 more
doaj   +1 more source

Prognostic significance of sarcopenia diagnosed based on the anthropometric equation for progression-free survival and overall survival in patients with colorectal cancer

Frontiers in Nutrition, 2023
BackgroundThe purpose of this study was to investigate the prognostic significance of sarcopenia diagnosed based on anthropometric equations for progression-free survival (PFS) and overall survival (OS) in patients with colorectal cancer (CRC).MethodsA ...
Hailun Xie, Hailun Xie, Lishuang Wei, Shunhui Gao, Shunhui Gao, Mingxiang Liu, Mingxiang Liu, Yanren Liang, Yanren Liang, Guanghui Yuan, Guanghui Yuan, Qiwen Wang, Qiwen Wang, Yansong Xu, Shuangyi Tang, Jialiang Gan, Jialiang Gan   +16 more
doaj   +1 more source

Chinese Medicine Combined With EGFR-TKIs Prolongs Progression-Free Survival and Overall Survival of Non-small Cell Lung Cancer (NSCLC) Patients Harboring EGFR Mutations, Compared With the Use of TKIs Alone [PDF]

, 2021
Yujia Wang, Guoyu Wu, Ru Li, Yingzhe Luo, Xingmei Huang, Li-Fang He, Huihui Zhong, Shaoquan Xiong   +7 more
openalex   +1 more source